Dear Sir,Triamcinolone acetonide（TA）is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenes...Dear Sir,Triamcinolone acetonide（TA）is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenesis inhibitors[1-2].展开更多
Objective:to observe the clinical effica-cy of Shenling Baizhu Powder(SLBZP)combined with a subconjunctival injection of triamcinolone acetonide(TA)in treating macular edema(ME)induced by retinal vein occlusion(RVO).M...Objective:to observe the clinical effica-cy of Shenling Baizhu Powder(SLBZP)combined with a subconjunctival injection of triamcinolone acetonide(TA)in treating macular edema(ME)induced by retinal vein occlusion(RVO).Method:there were 62 patients(62 eyes)with ME induced by RVO that were selected and divided into two groups in accordance with the ran-dom number table.Each group had 31 eyes.Group one,the control group,was treated with a single subconjunc-tival injection of TA;group two,the observation group,was treated with a single subconjunctival injection of TA(20 mg/0.5 mL)per eye and one month of SLBZP.To evaluate the clinical efficacy,both groups were checked(3×)with the best corrected-visual acuity(BCVA),cen-ter macular thickness(CMT),and intraocular pressure(IOP).The checks were before treatment,one month af-ter injection,and three months after injection.Results:there were 26 eyes(83.87%)in the observation group,and 17 eyes(54.84%)in the control group in which the BCVA was significantly improved.The ME obviously de-creased in 27 eyes(87.10%)the observation group and in 19 eyes(61.29%)the control group.The clinical effica-cy of the observation group was significantly better than that of the control group(P<0.05).Conclusion:as one method to treat ME induced by RVO,SLBZP combined with subconjunctival injection of TA is significantly more effective than a single subconjunctival injection of TA.Besides,the SLBZP had less side-effects.Based on the above,this method deserves in-depth research.展开更多
目的评估透明质酸钠与曲安奈德对兔膝骨性关节炎中关节滑膜及软骨的影响。方法 24只新西兰兔制造骨关节炎模型后按数表法随机分为对照组、透明质酸钠(SH)组、曲安奈德(TA)组,每组各8只,分别进行关节腔注射生理盐水0.4 m L、SH 0.4 m L、...目的评估透明质酸钠与曲安奈德对兔膝骨性关节炎中关节滑膜及软骨的影响。方法 24只新西兰兔制造骨关节炎模型后按数表法随机分为对照组、透明质酸钠(SH)组、曲安奈德(TA)组,每组各8只,分别进行关节腔注射生理盐水0.4 m L、SH 0.4 m L、TA 0.4 m L,每周一次,每组6次。6周后观察每组兔膝关节滑膜组织病理切片、血管滑膜SP法染色、软骨AB-PAS染色及MMP-1免疫组化。结果滑膜病理切片显示,SH组滑膜增生最少,TA组滑膜增生较少,对照组滑膜增生明显;滑膜SP法染色显示SH组、TA组VEGF阳性细胞百分数较对照组减少[(42.50±5.29)%、(50.80±5.24)%vs(53.38±4.75)%,P<0.05],SH组、TA组平均光密度值较对照组减少[(0.32±0.02)、(0.43±0.04)vs(0.48±0.05),P<0.05],TA组较SH组和对照组内软骨细胞减少,软骨基质成分减少,SH组、TA组较对照组软骨表层破坏减少。SH组、TA组软骨MMP-1细胞百分数评分优于对照组[(61.25±4.06)%、(76.27±4.68)%vs(87.13±3.64)%,P<0.05];SH组、TA组软骨Mankins评分优于对照组[(6.88±1.25)分、(7.27±0.68)分vs(8.13±0.83)分,P<0.05]。结论透明质酸钠和曲安奈德均能抑制滑膜炎增生,减少兔膝关节腔内的炎性细胞因子,减少了软骨基质的破坏,且透明质酸钠要优于曲安奈德。展开更多
目的:早产儿视网膜病变(Retinopathy of prematurity,ROP)是一种严重影响早产儿生存质量的疾病,目前对ROP的防治研究着重于抑制视网膜新生血管的形成,本实验通过建立高氧诱导的早产儿视网膜病变的动物模型,探讨长效糖皮质激素类药物曲...目的:早产儿视网膜病变(Retinopathy of prematurity,ROP)是一种严重影响早产儿生存质量的疾病,目前对ROP的防治研究着重于抑制视网膜新生血管的形成,本实验通过建立高氧诱导的早产儿视网膜病变的动物模型,探讨长效糖皮质激素类药物曲安奈德在抑制视网膜新生血管方面的作用。方法:选择鼠龄为7 d的C57 BL/6 J幼鼠60只,分为大、小剂量治疗组和正常及高氧对照组。大、小剂量治疗组一眼玻璃体腔内分别注射曲安奈德5μl及2.5μl,对侧眼注射相同体积的平衡盐溶液(BSS)作为对照。血管灌注法视网膜铺片,观察视网膜血管情况;视网膜组织切片HE染色观察并计数突破视网膜内界膜的血管内皮细胞核数目。结果:高氧环境对照组与正常环境对照组相比,视网膜有大量新生血管形成,说明高氧诱导的早产儿视网膜病变动物模型制作成功;药物治疗组与高氧对照组相比视网膜血管分布规则、密度减少,且突破视网膜内界膜的血管内皮细胞核数目明显减少(P<0.001)。大、小剂量治疗组相比差异不明显(P>0.05),视网膜组织切片未见视网膜毒性及炎症反应。结论:曲安奈德有抑制视网膜新生血管形成的作用。展开更多
文摘Dear Sir,Triamcinolone acetonide（TA）is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenesis inhibitors[1-2].
文摘Objective:to observe the clinical effica-cy of Shenling Baizhu Powder(SLBZP)combined with a subconjunctival injection of triamcinolone acetonide(TA)in treating macular edema(ME)induced by retinal vein occlusion(RVO).Method:there were 62 patients(62 eyes)with ME induced by RVO that were selected and divided into two groups in accordance with the ran-dom number table.Each group had 31 eyes.Group one,the control group,was treated with a single subconjunc-tival injection of TA;group two,the observation group,was treated with a single subconjunctival injection of TA(20 mg/0.5 mL)per eye and one month of SLBZP.To evaluate the clinical efficacy,both groups were checked(3×)with the best corrected-visual acuity(BCVA),cen-ter macular thickness(CMT),and intraocular pressure(IOP).The checks were before treatment,one month af-ter injection,and three months after injection.Results:there were 26 eyes(83.87%)in the observation group,and 17 eyes(54.84%)in the control group in which the BCVA was significantly improved.The ME obviously de-creased in 27 eyes(87.10%)the observation group and in 19 eyes(61.29%)the control group.The clinical effica-cy of the observation group was significantly better than that of the control group(P<0.05).Conclusion:as one method to treat ME induced by RVO,SLBZP combined with subconjunctival injection of TA is significantly more effective than a single subconjunctival injection of TA.Besides,the SLBZP had less side-effects.Based on the above,this method deserves in-depth research.
文摘目的评估透明质酸钠与曲安奈德对兔膝骨性关节炎中关节滑膜及软骨的影响。方法 24只新西兰兔制造骨关节炎模型后按数表法随机分为对照组、透明质酸钠(SH)组、曲安奈德(TA)组,每组各8只,分别进行关节腔注射生理盐水0.4 m L、SH 0.4 m L、TA 0.4 m L,每周一次,每组6次。6周后观察每组兔膝关节滑膜组织病理切片、血管滑膜SP法染色、软骨AB-PAS染色及MMP-1免疫组化。结果滑膜病理切片显示,SH组滑膜增生最少,TA组滑膜增生较少,对照组滑膜增生明显;滑膜SP法染色显示SH组、TA组VEGF阳性细胞百分数较对照组减少[(42.50±5.29)%、(50.80±5.24)%vs(53.38±4.75)%,P<0.05],SH组、TA组平均光密度值较对照组减少[(0.32±0.02)、(0.43±0.04)vs(0.48±0.05),P<0.05],TA组较SH组和对照组内软骨细胞减少,软骨基质成分减少,SH组、TA组较对照组软骨表层破坏减少。SH组、TA组软骨MMP-1细胞百分数评分优于对照组[(61.25±4.06)%、(76.27±4.68)%vs(87.13±3.64)%,P<0.05];SH组、TA组软骨Mankins评分优于对照组[(6.88±1.25)分、(7.27±0.68)分vs(8.13±0.83)分,P<0.05]。结论透明质酸钠和曲安奈德均能抑制滑膜炎增生,减少兔膝关节腔内的炎性细胞因子,减少了软骨基质的破坏,且透明质酸钠要优于曲安奈德。
